Differentiating Sarcopenia and Cachexia Among Patients With Cancer

@article{Peterson2017DifferentiatingSA,
  title={Differentiating Sarcopenia and Cachexia Among Patients With Cancer},
  author={Sarah J Peterson and M. Mozer},
  journal={Nutrition in Clinical Practice},
  year={2017},
  volume={32},
  pages={30–39}
}
Patients with cancer are at an increased risk for muscle loss via 2 distinct mechanisms: sarcopenia, defined as the age-associated decrease in muscle mass related to changes in muscle synthesis signaling pathways, and/or cachexia, defined as cytokine-mediated degradation of muscle and adipose depots. Both wasting disorders are prevalent; among patients with cancer, 15%–50% are sarcopenic and 25%–80% are cachectic. Muscle mass may be difficult to quantify in overweight/obese individuals. Often… Expand
Sarcopenia versus cancer cachexia: the muscle wasting continuum in healthy and diseased aging.
TLDR
Data retrieved from this analysis highlight that while sarcopenia is characterized by the atrophy of fast-twitch muscle fibers, in cancer cachexia an increase in the proportion ofFast-twitch fibers appears to happen, and the molecular drivers for these specificmuscle remodeling patterns are still unknown. Expand
Sarcopenia (and sarcopenic obesity) in older patients with gynecological malignancies.
TLDR
It is demonstrated that obesity can mask sarcopenia, taking into consideration a sample of older patient with cancer, unless body composition evaluation and comprehensive geriatric assessment, including measures of muscle strength and performance, is executed. Expand
Sarcopenia in patients with colorectal cancer: A comprehensive review.
TLDR
Addition of sarcopenia screening to the established clinical-pathological scores for patients undergoing oncological treatment (chemotherapy, radiotherapy or surgery) seems to be the next step for the best of care of CRC patients. Expand
Sarcopenia, sarcopenic obesity, myosteatosis as factors of poor prognosis in gastrointestinal tract tumors: review
TLDR
The article aimed at raising awareness of clinicians regarding the high prevalence of cancer cachexia and sarcopenia, sarcopenic obesity and myosteatosis in patients with GI tract tumors and discusses the influence of body composition on dose-limiting toxicity of chemotherapy. Expand
Sarcopenia, Malnutrition, and Cachexia: Adapting Definitions and Terminology of Nutritional Disorders in Older People with Cancer
TLDR
The purpose of this review is to provide an updated overview of the latest research and consensus definitions of sarcopenia, malnutrition, and cachexia and to discuss their implications for clinical practice in older patients with cancer. Expand
Cancer-Associated Muscle Wasting—Candidate Mechanisms and Molecular Pathways
TLDR
A growing body of evidence suggests that the tumor is the driver of muscle wasting by its elaboration of mediators that influence each of these pro-sarcopenic pathways. Expand
Sarcopenia
TLDR
Sarcopenia has become the focus of intense research aiming to translate current knowledge about its pathophysiology into improved diagnosis and treatment, with particular interest in the development of biomarkers, nutritional interventions, and drugs to augment the beneficial effects of resistance exercise. Expand
Different methods for diagnosis of sarcopenia and its association with nutritional status and survival in patients with advanced cancer in palliative care.
TLDR
Sarcopenia diagnosed by MUAMA and CC could predict mortality and CC proved to be the best prognostic method for estimating OS in patients with advanced cancer in palliative care. Expand
The potential therapeutic effects of creatine supplementation on body composition and muscle function in cancer.
TLDR
An overview of Cr physiology, the evidence on the use of Cr supplementation in various aging/clinical populations, mechanisms of action, and perspectives on the potential therapeutic role of Cr in the exercise oncology setting are provided. Expand
Muscoloskeletal aging, sarcopenia and cancer.
TLDR
It becomes increasingly important to try to understand and therefore differentiate conditions such as the loss of muscle mass linked to normal aging, an independent pathological condition such as sarcopenia and finally a sometimes confusing pathologic condition called cachexia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 113 REFERENCES
Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact
TLDR
Sarcopenia and sarcopenic obesity create diverse nutritional requirements, highlighting the compelling need for a more comprehensive and differentiated understanding of energy and protein requirements in this heterogeneous population. Expand
Cancer cachexia, mechanism and treatment.
TLDR
The emerging understanding of the mechanisms of cancer cachexia, the current treatment options including multidisciplinary combination therapies, as well an update on new and ongoing clinical trials are discussed. Expand
Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review
TLDR
This review highlights the common pathophysiological mechanisms underlying muscle loss in sarcopenia and cachexia, the factors unique to each condition and means of diagnosing and differentiating them clinically. Expand
Are there any benefits of exercise training in cancer cachexia?
TLDR
This editorial is aimed at stimulating the debate on the suitability of including exercise training in a multi-functional approach against cachexia taking into consideration both limitations and advantages. Expand
Understanding the mechanisms and treatment options in cancer cachexia
TLDR
The combination of therapies into a standard multimodal package coupled with the development of novel therapeutics promises a new era in supportive oncology whereby quality of life and tolerance to cancer therapy could be improved considerably. Expand
The cancer cachexia syndrome: a review of metabolic and clinical manifestations.
  • D. H. Esper, W. Harb
  • Medicine
  • Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
  • 2005
TLDR
The successful reversal of this process will require in-depth knowledge of the mechanisms involved, which will enable the development of effective pharmacologic interventions that may not only improve quality of life, but more importantly, improve survival among cancer patients. Expand
Sarcopenia and physical function in overweight patients with advanced cancer.
TLDR
This work investigated the prevalence of sarcopenia and its association with different portable and low-cost functional status measurement tools in overweight/obese patients (body mass index ≥ 25 kg/m2) with advanced cancer. Expand
Sarcopenia and physical function in overweight patients with advanced cancer.
TLDR
Handgrip strength was associated with sarcopenia in male patients with advanced cancer, and therefore it may be used as a portable and simple nutritional screening tool. Expand
Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.
TLDR
Patients with cancer who are cachexic by the conventional criterion and by two additional criteria (muscle depletion and low muscle attenuation) share a poor prognosis, regardless of overall body weight. Expand
Clinical Implications of Sarcopenic Obesity in Cancer
TLDR
The prevalence of sarcopenic obesity varied substantially: between 1 and 29 % in studies including individuals from all body mass index categories and between 15 and 36 % for those including obese individuals only. Expand
...
1
2
3
4
5
...